

## Tuesday, June 18, 2013

---

- 10:00 – 17:30 **ESO WORKSHOP: “MOLECULAR HETEROGENEITY AND TAILORED TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA” \***  
(**by invitation only** – USI Auditorium, University Campus Lugano)  
Steering Committee: F. Bertoni, Bellinzona (Switzerland), F.E. Cotter, London (UK), M.A. Shipp, Boston MA (USA), E. Zucca, Bellinzona (Switzerland)  
\* organized in co-operation with the European School of Oncology (ESO)
- 13:00 – 15:00  
(satellite symposium) **PHARMACYCLICS, INC. / JANSSEN PHARMACEUTICALS**  
**ADVANCEMENTS IN THE TREATMENT OF B-CELL MALIGNANCIES**  
(room BII)  
Chair: B.D. Cheson, Washington D.C. (USA)
- 15:30 – 18:00 **WORKSHOP: “MODERN RADIOTHERAPY FOR LYMPHOMAS – CONCEPTS AND TREATMENT GUIDELINES” \***  
(**open to all 12-ICML attendees** - room C)  
Chair: L. Specht, Copenhagen (Denmark)  
\* organized by ILROG - International Lymphoma Radiation Oncology Group
- 16:00 – 18:00  
(parallel satellite symposia) **GILEAD SCIENCES, INC. (supported by an unrestricted educational grant from)**  
**PI3 KINASE  $\delta$  INHIBITORS AND THEIR ROLE IN LYMPHOID MALIGNANCIES**  
(room BI)  
Chair: F. Cavalli, Bellinzona (Switzerland)
- PFIZER ONCOLOGY**  
**TREATING AGGRESSIVE LYMPHOMAS: BETWEEN GUIDELINES, CLINICAL TRIALS AND REAL LIFE** (room BII)  
Chair: M. Ghielmini, Bellinzona (Switzerland)
- 19:00 – 21:00  
(parallel satellite symposia) **F. HOFFMANN-LA ROCHE LIMITED**  
**INNOVATIONS IN ANTIBODY THERAPY FOR LYMPHOID MALIGNANCY**  
(room A)  
Chair: F. Cavalli, Bellinzona (Switzerland)
- CTI Life Sciences (symposium organised and funded by)**  
**CURRENT PERSPECTIVE ON THE TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE B-CELL NHL** (room BI)  
Chair: M. Ghielmini, Bellinzona (Switzerland)
- prIME Oncology (supported by an unrestricted educational grant from MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY)**  
**NEW OPPORTUNITIES AND NEW CHALLENGES IN IMPROVING OUTCOMES FOR PATIENTS WITH CD30+ HEMATOLOGIC MALIGNANCIES** (room BII)  
Chair: T. Illidge, Manchester (UK)

## Wednesday, June 19, 2013

---

8:30 – 12:00 **POSTER SET UP** (Marquee Parco Ciani)

9:00 – 10:30  
(2 parallel sessions)

### **EDUCATIONAL SYMPOSIA**

#### **DIFFUSE LARGE B-CELL LYMPHOMA SUBTYPES** (room A)

Chair: P.W.M. Johnson, Southampton (UK)

##### LECTURES:

- I. PATHOLOGICAL AND CLINICAL DIVERSITY IN DLBCL  
M.A. Piris, Santander (Spain)
- II. THERAPY OF DLBCL BASED ON GENOMICS  
L.M. Staudt, Bethesda, MD (USA)
- III. APPLYING MOLECULAR PHENOTYPING IN PRACTICE  
P.W.M. Johnson, Southampton (UK)

#### **MULTIPLE MYELOMA** (room B, Marquee Parco Ciani)

Chair: S.V. Rajkumar, Rochester MN (USA)

##### LECTURES:

- IV. INITIAL THERAPY OF MYELOMA  
S.V. Rajkumar, Rochester, MN (USA)
- V. MOLECULAR CLASSIFICATION AND RISK STRATIFICATION OF MYELOMA  
P.L. Bergsagel, Scottsdale, AZ (USA)
- VI. AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE THERAPY  
P. Moreau, Nantes (France)

9:00 – 9:45  
(3 parallel sessions)

### **MEET THE PROFESSOR**

- VII. MANAGEMENT OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN'S LYMPHOMA (Cinema Corso)  
A. Engert, Cologne (Germany)
- VIII. NEW MARKERS IN T-CELL LYMPHOMA: MORE ENTITIES OR MORE CONFUSION?  
(USI Auditorium, University Campus Lugano)  
P. Gaulard, Créteil (France)
- IX. CLL: NEW GENETIC MARKERS AS PROGNOSTIC FACTORS (USI Aula Magna, University Campus Lugano)  
D. Rossi, Novara (Italy)

10:00 – 10:45  
(3 parallel sessions)

### **MEET THE PROFESSOR**

- X. EXTRANODAL LYMPHOMAS IN RARE LOCALISATIONS (BONE, BREAST AND OTHERS) (Cinema Corso)  
J.F. Seymour, Melbourne (Australia)
- XI. HOW TO TREAT CHILDREN AND ADOLESCENTS WITH RELAPSED NON-HODGKIN LYMPHOMA? (USI Auditorium, University Campus Lugano)  
W. Woessmann, Giessen (Germany)
- XII. HODGKIN'S LYMPHOMA IN THE ELDERLY (USI Aula Magna, University Campus Lugano)  
A.M. Evens, Worcester, MA (USA)

- 10:45 – 11:10 **COFFEE BREAK** (Marquee Parco Ciani)
- 11:10 – 12:00 **CONTROVERSY I** (room A, B and Marquee)  
 IS R-CHOP THE STANDARD TREATMENT FOR HIGH RISK DLBCL?  
 Chair: U. Jäger, Wien (Austria)  
 004 YES – J. Friedberg, Rochester, NY (USA) vs  
 005 NO – F. Morschhauser, Lille (France)
- 12:00 – 18:30 **POSTER SESSION \*** (Marquee Parco Ciani)  
 \* printing of the posters sponsored by Mundipharma International Limited
- 161-171 MOLECULAR BIOLOGY  
 172-185 CLINICOPATHOLOGIC CORRELATIONS  
 186-204 INDOLENT ENTITIES  
 205-226 AGGRESSIVE B-CELL LYMPHOMA  
 227-231 MANTLE CELL LYMPHOMA  
 232-238 T-CELL LYMPHOMAS  
 239-251 EXTRANODAL LYMPHOMAS  
 252-256 HODGKIN'S LYMPHOMA  
 257-263 CLL  
 264-269 TRANSPLANTATION  
 270-276 IMAGING  
 277-285 NEW DRUGS PRE-CLINICAL  
 286-304 NEW DRUGS CLINICAL  
 305-310 PAEDIATRIC LYMPHOMA
- 12:00 – 13:00 **LUNCH TIME AND POSTER VIEWING** (Marquee Parco Ciani)
- 13:00 – 13:55 **OPENING OF THE CONFERENCE** (room A, B and Marquee Parco Ciani)   
 WELCOME AND INTRODUCTORY REMARKS  
 F. Cavalli, Bellinzona (Switzerland)
- 13:10 **HENRY KAPLAN MEMORIAL LECTURE**  
 supported by a special grant of the European School of Oncology Foundation - ESOF  
 Introduction to ESOF: C. Maggini, Bellinzona (Switzerland)  
 Laudatio: J.O. Armitage, Omaha, NE (USA)  
 001 THE EVOLUTION OF LYMPHOMA UNDERSTANDING AND TREATMENT FROM  
 1-ICML (1981) TO 12-ICML (2013)  
 F. Cavalli, Bellinzona (Switzerland)
- 14:00 – 15:00 **PLENARY SESSION** (room A, B and Marquee Parco Ciani)  
 Chairs: J.O. Armitage, Omaha, NE (USA) and F. Cavalli, Bellinzona (Switzerland)
- 14:00 006 ITERATIVE GERMINAL CENTER RE-ENTRIES OF MEMORY B-CELLS WITH T(14;18)  
 TRANSLOCATION AND EARLY STEPS OF FOLLICULAR LYMPHOMA  
 PROGRESSION  
 S. Roulland, Marseille (France)  
 Discussant: R. Gascoyne, Vancouver, BC (Canada)

- 14:20 007 CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENT-FREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY  
E. Zucca, Bellinzona (Switzerland)  
Discussant: G. Nowakowski, Rochester MN (USA)
- 14:40 008 SINGLE AGENT IBRUTINIB (PCI-32765) IS HIGHLY EFFECTIVE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH 17P DELETION  
A. Wiestner, Bethesda MD (USA)  
Discussant: S. Stilgenbauer, Ulm (Germany)
- 15:00 – 15:30 **COFFEE BREAK** (Marquee Parco Ciani)
- 15:30 – 17:00 **SESSION 1 – BIOLOGY OF DIFFUSE LARGE B-CELL LYMPHOMA**  
(room A, B and Marquee Parco Ciani)  
Chairs: F.E. Cotter, London (UK) and M.A. Shipp, Boston MA (USA)
- 15:30 009 EPSTEIN-BARR VIRUS (EBV) POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IS A NEOPLASM WITH PREFERENTIAL ACTIVATED GENE EXPRESSION SIGNATURE WHOSE OUTCOME RELIES ON CD30 EXPRESSION: A REPORT FROM THE INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY  
K.H. Young, Houston, TX (USA)
- 15:45 010 THERAPEUTIC TARGETING OF CELL CYCLE DEREGULATION IN DIFFUSE LARGE B-CELL LYMPHOMA  
B. Chapuy, Boston MA (USA)
- 16:00 011 INTEGRATED ANALYSIS IDENTIFIED DELETION OF CDKN2A AS THE MOST FREQUENT AND UNIQUE GENOMIC ABNORMALITY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH STRONG PROGNOSTIC VALUE NOT OVERCOME BY A DOSE-INTENSIVE IMMUNOCHEMOTHERAPY. A LYSA STUDY  
F. Jardin, Rouen (France)
- 16:15 012 BIOLOGIC CHARACTERIZATION OF ADULT MYC-POSITIVE MATURE B-CELL LYMPHOMAS OTHER THAN MOLECULAR BURKITT LYMPHOMA WITHIN THE MMML COHORT  
S.M. Aukema, Kiel (Germany)
- 16:30 013 INTEGRATED SEQUENCE ANALYSES OF BURKITT, FOLLICULAR AND DIFFUSE LARGE B-CELL LYMPHOMAS IN THE FRAMEWORK OF THE GERMAN ICGC MMML-SEQ  
R. Siebert, Kiel (Germany)
- 16:45 **REPORT OF ESO WORKSHOP ON “MOLECULAR HETEROGENEITY AND TAILORED TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA”**  
M.A. Shipp, Boston MA (USA)
- 17:15 – 18:15 **“FOCUS ON...” SESSIONS**  
(6 parallel sessions) **PET-GUIDED TREATMENT DECISIONS** (room A)  
Chair: T.A. Lister, London (UK)

- 17:15 014 DOES QUANTITATIVE PET-CT PREDICT PROGNOSIS IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)?  
N.G. Mikhaeel, London (UK)
- 17:25 015 FINAL RESULTS OF A PROSPECTIVE EVALUATION OF THE PREDICTIVE VALUE OF INTERIM PET IN PATIENTS WITH DLBCL UNDER R-CHOP-14 (SAKK 38/07)  
C. Mamot, Aarau (Switzerland)
- 17:35 016 RESPONSE-ADAPTED THERAPY AND PREDICTIVE VALUE OF MID-TREATMENT PET SCANNING FOR DIFFUSE LARGE B-CELL LYMPHOMA. ECOG STUDY E3404  
L.J. Swinnen, Baltimore, MD (USA)
- 17:45 017 EVALUATION OF DUAL TRACER (FLT AND FDG) PET IMAGING AS PART OF RISK-ADAPTED THERAPY FOR PATIENTS (PTS) WITH ADVANCED STAGE DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)  
C.H. Moskowitz, New York, NY (USA)
- 17:55 018 PET-CT FOR STAGING AND EARLY RESPONSE – RESULTS FROM THE RESPONSE ADAPTED THERAPY IN ADVANCED HODGKIN LYMPHOMA (RATHL) STUDY  
S.F. Barrington, London (UK)
- 18:05 019 INTERIM RESULTS OF IIL-HD0801 STUDY ON EARLY SALVAGE WITH HIGH-DOSE CHEMOTHERAPY AND STEM CELL TRANSPLANTATION IN ADVANCED STAGE HODGKIN'S LYMPHOMA PATIENTS WITH POSITIVE POSITRON EMISSION TOMOGRAPHY AFTER TWO COURSES OF CHEMOTHERAPY  
P.L. Zinzani, Bologna (Italy)
- 17:15 – 18:15 **TRANSPLANT STRATEGIES** (room B)  
Chair: S. Le Gouill, Nantes (France)
- 17:15 020 BENDAMUSTIN AS PART OF CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH AGGRESSIVE LYMPHOMAS: A PHASE 2 STUDY FROM SPANISH GELTAMO GROUP  
A. Martin, Salamanca (Spain)
- 17:25 021 HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION  
D. Chihara, Nagoya (Japan)
- 17:35 022 TREATMENT OUTCOMES FOR OLDER PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA RECEIVING SALVAGE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE SIMILAR TO YOUNGER PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE III NCIC CTG LY12 TRIAL  
K. Davison, Toronto, Ontario (Canada)

- 17:45 023 CORD BLOOD TRANSPLANTATION FOR ADULT T-CELL LEUKEMIA/LYMPHOMA (ATL): A RETROSPECTIVE ANALYSIS FROM THE ATL WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION  
K. Kato, Fukuoka (Japan)
- 17:55 024 OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMA WITH CONCURRENT MYC AND BCL2 TRANSLOCATIONS: A SINGLE CENTRE RETROSPECTIVE ANALYSIS  
M. Greenwood, Sydney (Australia)
- 18:05 025 LONG TERM OUTCOMES AFTER FLUDA/CYCLOPHOSPHAMIDE REDUCED-INTENSITY CONDITIONING (RIC) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR LYMPHOMAS : A BHS NATIONAL PROSPECTIVE TRIAL  
D. Bron, Antwerpen (Belgium)
- 17:15 – 18:15 **PRECLINICAL ASSAYS** (room C)  
Chair: G. Gaidano, Novara (Italy)
- 17:15 026 BIOMIMETIC SYNTHETIC HIGH DENSITY LIPOPROTEIN NANOSTRUCTURES TARGET THE SR-B1 RECEPTOR, DIFFERENTIALLY MANIPULATE CELLULAR CHOLESTEROL FLUX IN LYMPHOMA CELLS, AND MODIFY CELL CYCLE, OXIDATION AND CHOLESTEROL SYNTHESIS GENES  
L.I. Gordon, Chicago, IL (USA)
- 17:25 027 CROSS-SPECIES DISSECTION OF FUNCTION, MECHANISM AND PREDICTIVE IMPACT OF THERAPY-RELATED PARACRINE SENESENCE IN AGGRESSIVE B-CELL LYMPHOMA IN MICE AND MEN  
C.A. Schmitt, Berlin (Germany)
- 17:35 028 THE NOVEL PROTEASOME INHIBITOR LU-102, BUT NOT BORTEZOMIB OR CARFILZOMIB, DECREASES P-IKB LEVELS IN MYELOMA CELLS, AND IS SYNERGISTIC WITH IBRUTINIB TO OVERCOME BORTEZOMIB/CARFILZOMIB RESISTANCE IN VITRO  
J. Kraus, St. Gallen (Switzerland)
- 17:45 029 DUAL TARGETING OF PROTEIN DEGRADATION PATHWAYS WITH THE SELECTIVE HDAC6 INHIBITOR, ACY-1215 (ACY), AND BORTEZOMIB (BOR), DEMONSTRATES SYNERGISTIC ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF LYMPHOMA  
J.E. Amengual, New York, NY (USA)
- 17:55 030 THE NOVEL 2ND GENERATION PROTEASOME INHIBITOR MLN9708 INDUCES REDOX- AND MAPK-RELATED CELL DEATH IN T-CELL LYMPHOMA (TCL) AND HODGKIN LYMPHOMA (HL) CELL LINES AND HUMAN LYMPHOMA XENOGRAFT MODELS  
A.M. Evens, Worcester, MA (USA)
- 18:05 031 PHARMACOLOGIC INHIBITION OF MALT1 BY DISTINCT PHENOTHIAZINES FOR A TARGET-DIRECTED THERAPY OF ABC-DLBCL  
D. Nagel, Neuherberg (Germany)

- 17:15 – 18:15 **EARLY AND LATE TOXICITIES** (Cinema Corso)  
Chair: A. Moccia, Bellinzona (Switzerland)
- 17:15 032 IMMUNOCHEMOTHERAPY WITH BENDAMUSTINE-RITUXIMAB (B-R) AS INDUCTION THERAPY FOR INDOLENT LYMPHOMAS RESULTS IN A SEVERE LYMPHOPENIA WITH LOW CD4+ AND CD8+ COUNTS WITHOUT AN INCREASE IN ATYPICAL INFECTIONS. FIRST RESULTS OF THE INFECTIOUS DISEASE (ID) PROJECT OF A PROSPECTIVE, RANDOMIZED, MULTICENTER STUDY (STIL NHL 7-2008 –MAINTAIN-; NCT00877214)  
A. Burchardt, Giessen (Germany)
- 17:25 033 RISK OF DIABETES MELLITUS FOLLOWING TREATMENT OF HODGKIN LYMPHOMA  
B.M. Aleman, Amsterdam (Netherlands)
- 17:35 034 DOSES TO CAROTID ARTERIES AFTER MODERN RADIOTHERAPY FOR HODGKIN LYMPHOMA: IS STROKE STILL A LATE EFFECT OF TREATMENT?  
M.V. Maraldo, Copenhagen (Denmark)
- 17:45 035 RISK FACTORS FOR VALVULAR HEART DISEASE FOLLOWING HODGKIN LYMPHOMA  
D.J. Cutter, Oxford (UK)
- 17:55 036 INCREASED STOMACH CANCER RISK AFTER TREATMENT FOR HODGKIN LYMPHOMA  
F. van Leeuwen, Amsterdam (Netherlands)
- 18:05 037 SECOND PRIMARY MALIGNANCIES (SPM) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A METAANALYSIS OF FOUR PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP  
P. Langerbeins, Cologne (Germany)
- 17:15 – 18:05 **NOVEL MONOCLONAL ANTIBODIES** (USI Auditorium, University Campus Lugano)  
Chair: M. Czuczman, Buffalo, NY (USA)
- 17:15 038 NOVEL PI3K- $\delta$  INHIBITORS DEMONSTRATED MARKED CYTOTOXICITY IN T CELL LYMPHOMA MODELS AND WERE SYNERGISTIC WITH A NOVEL ANTI-CD20 MAB, UBLITUXIMAB, IN LYMPHOMA MODELS  
C. Deng, New York NY (USA)
- 17:25 039 PHASE I STUDY OF THE ANTI-CD22 ANTIBODY-DRUG CONJUGATE (ADC) DCDT2980S WITH OR WITHOUT RITUXIMAB (RTX) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN'S LYMPHOMA (NHL)  
R. Advani, Stanford, CA (USA)
- 17:35 040 PHASE I STUDY OF THE ANTI-CD79B ANTIBODY-DRUG CONJUGATE DCDS4501A IN RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN'S LYMPHOMA (NHL)  
M.C. Palanca-Wessels, Seattle, WA (USA)

- 17:45 041 THE EFFICACY AND SAFETY OF MOGAMULIZUMAB(KW-0761) IN MULTICENTER PHASE II STUDY FOR PATIENTS WITH RELAPSED PERIPHERAL OR CUTANEOUS T-CELL LYMPHOMA  
R. Ueda, Nagakute (Japan)
- 17:55 042 A PHASE I STUDY OF BISPECIFIC CD30/CD16A TANDAB ANTIBODY AFM13 IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA  
A. Engert, Cologne (Germany)
- 17:15 – 18:15 **LYMPHOMA AND THE CNS** (USI Aula Magna, University Campus Lugano)  
Chair: A. Ferreri, Milan (Italy)
- 17:15 043 DEVELOPMENT OF NOVEL PATIENT-DERIVED XENOGRAPTS TO DISSECT THE PATHOGENESIS OF CNS LYMPHOMA  
J. Rubenstein, San Francisco, CA (USA)
- 17:25 044 HIGH EFFICIENCY OF ICE (IFOSFAMIDE-CARBOPLATIN-ETOPOSIDE) IN RELAPSE/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM AND INTRA-OCULAR NON HODGKIN LYMPHOMA, AFTER FIRST LINE TREATMENT CONTAINING HIGH DOSES OF METHOTREXATE (MTX) AND CYTARABINE (ARAC). A MULTICENTRIC RETROSPECTIVE STUDY FROM 2010 TO 2012 ON 34 CASES. A LOC NETWORK STUDY  
S. Choquet, Paris (France)
- 17:35 045 RITUXIMAB, METHOTREXATE, PROCARBAZINE, VINCRISTINE AND INTENSIFIED CYTARABINE CONSOLIDATION FOR PRIMARY CNS LYMPHOMA (PCNSL) IN THE ELDERLY: A LOC NATIONAL NETWORK STUDY (INCA)  
C. Houillier, Paris (France)
- 17:45 046 PHASE II TRIAL OF TEMSIROLIMUS FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)  
P. Kiewe, Berlin (Germany)
- 17:55 047 A NEW PROGNOSTIC MODEL TO ASSESS THE RISK OF CNS DISEASE IN PATIENTS WITH AGGRESSIVE B CELL LYMPHOMA  
N. Schmitz, Hamburg (Germany)
- 18:05 048 EXTRALYMPHATIC CRANIOFACIAL DIFFUSE LARGE B-CELL LYMPHOMA: ROLE OF RADIOTHERAPY AND INTRATHECAL CNS PROPHYLAXIS  
N. Murawski, Homburg (Germany)
- 19:00 – 21:00  
(2 parallel satellite symposia) MUNDIPHARMA INTERNATIONAL LTD.  
**MAKING SENSE OF THE RAPIDLY CHANGING WORLD OF LYMPHOMA**  
(room A)  
Chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Czuczman, Buffalo, NY (USA)
- CELGENE CORPORATION  
**FROM BENCH TO BEDSIDE – TRANSLATING PRECLINICAL RESEARCH INTO CLINICAL REALITY** (room B)  
Chair: B.D. Cheson, Washington D.C. (USA)



## Thursday, June 20, 2013

---

8:30 – 18:30 **POSTER SESSION** (Marquee Parco Ciani)

8:00 – 8:45 **MEET THE PROFESSOR SESSIONS** 

(5 parallel sessions, repetition of some of Wednesday session)

- XIII. WALDENSTRÖM MACROGLOBULINEMIA: JUST ANOTHER INDOLENT LYMPHOMA? (room A)  
S.P. Treon, Boston, MA (USA)
- XIV. THE RATIONALE FOR COMBINING TARGETED AND BIOLOGICAL ANTI-LYMPHOMA DRUGS (room B)  
A. Younes, New York, NY (USA)
- XV. MALIGNANT LYMPHOMA AS A CONSEQUENCE OF CLONAL EVOLUTION (Cinema Corso)  
M. Seto, Nagoya (Japan)
- II. NEW MARKERS IN T-CELL LYMPHOMA: MORE ENTITIES OR MORE CONFUSION?  
(USI Auditorium, University Campus Lugano)  
P. Gaulard, Créteil (France)
- XVI. CNS PROPHYLAXIS IN AGGRESSIVE LYMPHOMAS: FOR WHOM AND HOW  
(USI Aula Magna, University Campus Lugano)  
U. Vitolo, Turin (Italy)

9:00 – 10:30 **SESSION 2 – CLL BIOLOGY** (room A, Marquee Parco Ciani)

Chairs: J. Gribben, London (UK) and M. Hallek, Cologne (Germany)

- 9:00 049 ASSOCIATION BETWEEN MOLECULAR LESIONS AND SPECIFIC B-CELL RECEPTOR SUBSETS IN CHRONIC LYMPHOCYTIC LEUKEMIA  
D. Rossi, Novara (Italy)
- 9:15 050 MICRORNA MIR-150 CONTRIBUTES TO THE DISEASE AGGRESSIVENESS AND REGULATION OF B-CELL RECEPTOR SIGNALING (BCR) IN CHRONIC LYMPHOCYTIC LEUKEMIA  
M. Mraz, San Diego, CA (USA)
- 9:30 051 IDENTIFICATION OF CIRCULATING CHRONIC LYMPHOCYTIC LEUKEMIA INTRACLONAL SUBGROUPS WITH VARYING B CELL RECEPTOR FUNCTION  
F. Forconi, Southampton (UK)
- 9:45 052 IMPACT OF INITIAL CLINICOBIOLOGICAL FEATURES, INCLUDING GENETIC MUTATIONS, IN THE DEVELOPMENT OF ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIA OR TRANSFORMATION TO DIFFUSE LARGE B CELL LYMPHOMA IN CLL  
E. Gine, Barcelona (Spain)
- 10:00 053 CLINICAL IMPACT OF MUTATIONS IN GENES OF THE TOLL-LIKE RECEPTOR (TLR/MYD88) PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)  
A. Martinez-Trillos, Barcelona (Spain)

10:15 054 OVER-EXPRESSION OF TP53 MRNA IN CHRONIC LYMPHOCYTIC LEUKAEMIA IS ASSOCIATED WITH LOW 13Q14 COPY NUMBER, REDUCED MIR-15A/16-1 LEVELS AND ADVERSE OUTCOME  
K. Lin, Liverpool (UK)

9:00 – 10:30  
(5 parallel sessions)

**“CASE DISCUSSION” SESSIONS**

**INDOLENT LYMPHOMAS** (room B)

Chair: M. Ghielmini, Bellinzona (Switzerland)

Discussants: F. Morschhauser, Lille (France) and T.E. Witzig, Rochester, MN (USA)

**PEDIATRIC AND ADOLESCENT LYMPHOMAS** (room C)

Chair: A. Reiter, Giessen (Germany)

Discussants: C. Patte, Villejuif (France) and S. Weitzman, Toronto, Ontario (Canada)

**T-CELL LYMPHOMAS** (Cinema Corso)

Chair: J. Seymour, Melbourne (Australia)

Discussants: S. M. Ansell, Rochester, MN (USA) and R. Delarue, Paris (France)

**MULTIPLE MYELOMA** (USI Auditorium, University Campus Lugano)

Chair: S.P. Treon, Boston, MA (USA)

Discussants: S.K. Kumar, Rochester, MN (USA) and P. Moreau, Nantes (France)

**HODGKIN LYMPHOMAS** (USI Aula Magna, University Campus Lugano)

Chair: M. Federico, Modena (Italy)

Discussants: M.P.E. André, Leuven (Belgium) and I.N. Micallef, Rochester, MN (USA)

10:30 – 10:50 **COFFEE BREAK** (Marquee Parco Ciani)

10:50 – 12:05 **SESSION 3 – ADVANCES IN THE CLINICAL MANAGEMENT OF CLL**  
(room A, B, Marquee)


Chairs: E. Montserrat, Barcelona (Spain) and J.C. Byrd, Columbus, OH (USA)

10:50 055 DEVELOPMENT OF A COMPREHENSIVE PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)  
J. Bahlo, Cologne (Germany)

11:05 056 OBINUTUZUMAB (GA101) + CHLORAMBUCIL (CLB) OR RITUXIMAB (R) + CLB VERSUS CLB ALONE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND PRE-EXISTING MEDICAL CONDITIONS (COMORBIDITIES): FINAL STAGE 1 RESULTS OF THE CLL11 (BO21004) PHASE 3 TRIAL  
M. Hallek, Cologne (Germany)

11:20 057 UPDATED RESULTS OF A PHASE I FIRST-IN-HUMAN STUDY OF THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)  
J. Seymour, Melbourne (Australia)

11:35 058 CORRELATION BETWEEN TP53 MUTATION OR DELETION AND EFFICACY WITH SINGLE-AGENT LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY (REL/REF) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (CC-5013-CLL-009 STUDY)  
A. Buhler, Cologne (Germany)

- 11:50 059 EVIDENCE THAT ALLOGENEIC TRANSPLANTATION (ALLOHCT) CAN IMPROVE THE NATURAL COURSE OF POOR-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS FROM A RETROSPECTIVE DONOR VS NO DONOR COMPARISON  
P. Dreger, Heidelberg (Germany)
- 12:05 – 13:00 **LUNCH TIME AND PRESENTATION OF BEST “PRE-CLINICAL” POSTERS**  
(Marquee Parco Ciani)  
by R. Dalla-Favera, New York, NY (USA)  
POSTERS # 168, 170, 177, 180, 228 and 240
- 13:00 – 13:50 **HENRY RAPPAPORT LECTURE** (room A, B, Marquee Parco Ciani)   
Chair: P. Gaulard, Créteil (France)  
002 ILLUMINATING THE INCIPIENT EVENTS IN LYMPHOID NEOPLASMS  
E.S. Jaffe, Bethesda, MD (USA)
- 13:50-15:20 **SESSION 4 – FOLLICULAR LYMPHOMA** (room A, B and Marquee)  
Chairs: A. Lopez Guillermo, Barcelona (Spain) and M. Seto, Nagoya (Japan)
- 13:50 060 THE STRUCTURE OF STEPWISE CLONAL EVOLUTION EVENTS SHAPING FOLLICULAR LYMPHOMA CODING GENOMES  
A.A. Alizadeh, Stanford, CA (USA)
- 14:05 061 GENOMIC ANALYSIS REVEALS THE EVOLUTION PATTERNS AND KEY PATHWAYS FUNDAMENTAL FOR THE INITIATION AND PROGRESSION OF FOLLICULAR LYMPHOMA  
J. Okosun, London (UK)
- 14:20 062 MANAGING STAGE I-II FOLLICULAR LYMPHOMA WITH UPFRONT DEFINITIVE RADIATION THERAPY: THE FORTY-YEAR EXPERIENCE OF THE PRINCESS MARGARET CANCER CENTRE  
A. Charpentier, Toronto, Ontario (Canada)
- 14:35 063 CALGB 50803(ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA  
P. Martin, New York, NY (USA)
- 14:50 064 SALVAGE CHEMOTHERAPY (SC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR TRANSFORMED INDOLENT LYMPHOMA (TR): A SUBGROUP ANALYSIS OF NCIC CTG LY12  
J. Kuruvilla, Toronto, Ontario (Canada)
- 15:05 064bis INTERIM RESULTS FROM A PHASE 2 STUDY OF PI3K INHIBITOR IDELALISIB IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (INHL) REFRACTORY TO BOTH RITUXIMAB AND AN ALKYLATING AGENT.  
G. Salles, Pierre Benite (France)
- 15:20 – 15:35 **COFFEE BREAK** (Marquee Parco Ciani)

- 15:35 – 17:05 **SESSION 5 – TARGETING THE BCR-NFKB PATHWAYS** (room A and Marquee)  
Chairs: G. Salles, Pierre Bénite (France) and L.M. Staudt, Bethesda, MD (USA)
- 15:35 Introduction: L.M. Staudt, Bethesda, MD (USA)
- 15:50 065 THE IKB FAMILY MEMBER NFKBIZ REGULATES NF-KB SIGNALING AND IS CRITICAL FOR SURVIVAL OF ABC DLBCL  
G. Lenz, Berlin (Germany)
- 16:05 066 PRELIMINARY SAFETY AND EFFICACY OF IPI-145, A POTENT INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE- $\delta$ , $-\gamma$ , IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA  
B. Kahl, Madison, WI (USA)
- 16:20 067 A PROSPECTIVE, MULTICENTER, PHASE II STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH RELAPSED AND REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA  
S.P. Treon, Boston, MA (USA)
- 16:35 068 COMBINATIONS OF THE PI3K $\delta$  INHIBITOR IDELALISIB (GS-1101) WITH RITUXIMAB AND/OR BENDAMUSTINE ARE TOLERABLE AND HIGHLY ACTIVE IN PATIENTS WITH PREVIOUSLY TREATED, INDOLENT NON-HODGKIN LYMPHOMA (INHL): UPDATED RESULTS FROM A PHASE I STUDY  
J.P. Leonard, New York, NY (USA)
- 16:50 069 PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)  
A. Younes, New York, NY (USA)
- 15:35 – 17:05 **SESSION 6 – PATHOLOGY AND CLINICOPATHOLOGIC CORRELATIONS** (room B)  
Chairs: S.A. Pileri, Bologna (Italy) and S. Dirnhofer, Basel (Switzerland)
- 15:35 070 CLASSIFICATION OF NON-HODGKIN LYMPHOMA IN SIX GEOGRAPHIC REGIONS AROUND THE WORLD: REVIEW OF 4539 CASES FROM THE INTERNATIONAL NON-HODGKIN LYMPHOMA CLASSIFICATION PROJECT  
A. Perry, Winnipeg, Manitoba (Canada)
- 15:50 071 SPLENIC DIFFUSE RED PULP LYMPHOMA HAS A DISTINCT PATTERN OF SOMATIC MUTATIONS AMONGST B-CELL MALIGNANCIES  
A. Traverse-Glehen, Pierre Bénite (France)
- 16:05 072 IN SITU FOLLICULAR LYMPHOMA: A GENETIC VIEWPOINT  
E. Mamessier, Marseille (France)
- 16:20 073 T(14;18) TRANSLOCATION: A PREDICTIVE BLOOD BIOMARKER FOR FOLLICULAR LYMPHOMA  
S. Roulland, Marseille (France)

- 16:35 074 THE HOST GENETIC BACKGROUND MODULATES TREATMENT ACTIVITY AND TOXICITY IN FOLLICULAR LYMPHOMA: FIL-FOLL05 TRIAL  
G.A. Palumbo, Catania (Italy)
- 16:50 075 STUDY ON THE BIOLOGY AND TREATMENT OF MEDIASTINAL GREY ZONE LYMPHOMA  
K. Dunleavy, Bethesda, MD (USA)
- 15:35 – 18:05 **SESSION 7 - PAEDIATRIC LYMPHOMA** (room C)  
Chair: A. Reiter, Giessen (Germany)
- 15:35 076 ALK TYROSINE KINASE INHIBITORS FOR ALK+ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): PRELIMINARY CLINICAL EXPERIENCES AND PERSPECTIVES  
T.G. Gross, Columbus, OH (USA)
- 16:05 077 MECHANISMS OF RESISTANCE TO ALK TYROSINE KINASE INHIBITORS AND STRATEGIES TO OVERCOME THEM  
R. Chiarle, Turin (Italy)
- 16:35 078 DETECTION OF ANTI-NPM-ALK CD8<sup>+</sup> T CELLS IN CHILDREN WITH NPM-ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)  
V.K. Singh, Giessen (Germany)
- 16:50 079 CNS DISEASE IN PEDIATRIC PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA AND BURKITT LEUKEMIA – THERAPY AND OUTCOME IN THE B-NHL BFM 04 STUDY  
J. Lisfeld, Giessen (Germany)
- 17:05 080 DIFFERENT PATTERN OF CHROMOSOMAL ALTERATIONS ACCORDING TO THE MORPHOLOGY AND THE AGE IN CHILDHOOD MATURE B-CELL LYMPHOMAS : REPORT OF THE FRENCH LMB2001/03 STUDY  
H.A. Poirel, Brussels (Belgium)
- 17:20 081 PEDIATRIC BURKITT LYMPHOMA OF THE NHL-BFM GROUP ANALYZED WITHIN THE ICGC-MMML-SEQ: WHOLE GENOME SEQUENCING DATA FROM 12 CASES  
M. Rohde, Giessen (Germany)
- 17:35 082 TEN-YEAR FOLLOW UP OF PEDIATRIC PATIENTS WITH NON-HODGKIN LYMPHOMA TREATED WITH ALLOGENEIC OR AUTOLOGOUS STEM CELL TRANSPLANTATION  
L.G. Roth, New York, NY (USA)
- 17:50 083 CLINICAL PRESENTATION AND OUTCOME OF ADVANCED STAGE CLASSICAL HODGKIN'S LYMPHOMA IN CHILDREN: A RETROSPECTIVE STUDY  
A.S. Dongre, Mumbai (India)
- 17:15 – 18:15  
(5 parallel sessions) **"FOCUS ON..." SESSIONS**  
**OLD & NEW RANDOMISED TRIALS** (room A)  
Chair: B. Coiffier, Pierre Bénite (France)

- 17:15 084 THE BRIGHT STUDY OF FIRST-LINE BENDAMUSTINE-RITUXIMAB (BR) OR R-CHOP/R-CVP IN ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA (NHL) OR MANTLE CELL LYMPHOMA (MCL)  
I. Flinn, Nashville, TN (USA)
- 17:25 085 GEMCITABINE, DEXAMETHASONE, CISPLATIN (GDP) COMPARED TO DEXAMETHASONE, CYTARABINE, CISPLATIN (DHAP) SALVAGE CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY AGGRESSIVE LYMPHOMAS: FINAL RESULTS OF THE PHASE III NCIC CTG STUDY LY12  
M. Crump, Toronto, Ontario (Canada)
- 17:35 086 ALTERNATING COURSES OF 3X CHOP AND 3X DHAP PLUS RITUXIMAB FOLLOWED BY A HIGH DOSE ARA-C CONTAINING MYELOABLATIVE REGIMEN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INCREASES OVERALL SURVIVAL WHEN COMPARED TO 6 COURSES OF CHOP PLUS RITUXIMAB FOLLOWED BY MYELOABLATIVE RADIOCHEMOTHERAPY AND ASCT IN MANTLE CELL LYMPHOMA: FINAL ANALYSIS OF THE MCL YOUNGER TRIAL OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK (MCL NET)  
O.R. Hermine, Paris (France)
- 17:45 087 PRELIMINARY RESULTS OF PROSPECTIVE RANDOMIZED MULTICENTER STUDY "BEACOPP-14 VS BEACOPP-ESCALATED IN PATIENTS WITH HODGKINS LYMPHOMA FROM POOR-PROGNOSIS GROUP"  
I.A. Kriachok, Kiev (Ukraine)
- 17:55 088 FIRST-LINE R-CVP VERSUS R-CHOP INDUCTION THERAPY AND MAINTENANCE RITUXIMAB FOR INDOLENT LYMPHOMA. A MULTICENTER PHASE III RANDOMIZED STUDY PLRG-4 BY THE POLISH LYMPHOMA RESEARCH GROUP  
J. Walewski, Warsaw (Poland)
- 18:05 089 BORTEZOMIB MAINTENANCE (BM) VS CONSOLIDATION (BC) FOLLOWING AGGRESSIVE IMMUNOCHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR UNTREATED MANTLE CELL LYMPHOMA (MCL): CALGB 50403  
L.D. Kaplan, San Francisco, CA (USA)
- 17:15 – 18:15 **LYMPHOMA GENOMICS** (room B)  
Chair: M.A. Piris, Santander (Spain)
- 17:15 090 HIGH RESOLUTION CHIP-SEQUENCING REVEALS NOVEL TARGETS AND PROGNOSTIC ROLE FOR SOX11 IN MANTLE CELL LYMPHOMA  
S. Parekh, New York, NY (USA)
- 17:25 091 DEREGULATION OF ETS1 AND FLI1 EXPRESSION IS RECURRENT IN DLBCL LEADING TO TUMOR PROLIFERATION AND B-CELL MATURATION BLOCKAGE  
M. Testoni, Bellinzona (Switzerland)
- 17:35 092 CONDITIONAL ACTIVATION OF THE HODGKIN LYMPHOMA-ASSOCIATED HLH FACTORS ID2 AND ABF1 DISRUPTS B CELL DIFFERENTIATION IN VIVO  
M. Janz, Berlin (Germany)

- 17:45 093 RECURRING ACTIVATION MUTATIONS AND SOMATIC DELETIONS REVEALED THROUGH WHOLE GENOME SEQUENCING IN WALDENSTRÖM'S MACROGLOBULINEMIA  
Z. Hunter, Boston, MA (USA)
- 17:55 094 PLCG1 MUTATIONS IN CUTANEOUS T-CELL LYMPHOMAS  
M. Sanchez-Beato, Madrid (Spain)
- 18:05 095 NEXT-GENERATION SEQUENCING SUGGESTS THERAPEUTIC TARGETS IN PERIPHERAL T-CELL LYMPHOMA  
J.H. Schatz, Tucson, AZ (USA)
- 17:15 – 18:15 **EXTRANODAL LESIONS** (Cinema Corso)  
Chair: C. Thieblemont, Paris (France)
- 17:15 096 PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE (PCDLBCL-LT) HARBOURS THE GENETIC PROFILE OF NODAL ACTIVATED B-CELL DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL)  
A. Pham-Ledard, Pessac (France)
- 17:25 097 THE ROLE OF RITUXIMAB AND PET IN THE TREATMENT OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA  
P. Zinzani, Bologna (Italy)
- 17:35 098 THE IMPACT OF RITUXIMAB AND RADIOTHERAPY ON OUTCOME OF PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA AND SKELETAL INVOLVEMENT  
G. Held, Homburg (Germany)
- 17:45 099 A PROSPECTIVE PHASE II TRIAL OF AN L-ASPARAGINASE CONTAINING REGIMEN IN EXTRA NODAL NK/T-CELL LYMPHOMA  
A. Jaccard, Limoges (France)
- 17:55 100 BENDAMUSTINE PLUS RITUXIMAB IN FIRST LINE SYSTEMIC TREATMENT FOR EXTRANODAL MALT LYMPHOMA: FINAL RESULTS OF PHASE II TRIAL OF THE SPANISH LYMPHOMA STUDY GROUP (GELTAMO)  
A. Salar, Barcelona (Spain)
- 18:05 101 CLINICAL OUTCOMES AND PATTERNS OF RELAPSE IN 320 PATIENTS WITH EARLY AND ADVANCED-STAGE MARGINAL ZONE LYMPHOMA: THE ROLE OF RADIOTHERAPY  
S. Teckie, New York, NY (USA)
- 17:15 – 18:15 **TREATING THE ELDERLY PATIENT** (USI Auditorium, University Campus Lugano)  
Chair: T.E. Witzig, Rochester, MN (USA)
- 17:15 102 DISEASE CHARACTERISTICS, PATTERNS OF CARE, AND OUTCOMES OF FOLLICULAR LYMPHOMA (FL) IN THE OLDEST OLD: REPORT FROM THE US NATIONAL LYMPHOCARE STUDY (NLCS)  
C. Nabhan, Park Ridge, IL (USA)

- 17:25 103 INFERIOR OUTCOME OF ELDERLY DLBCL PATIENTS WITH 25-OH VITAMIN D DEFICIENCY TREATED WITH CHOP PLUS RITUXIMAB (R): RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)  
J.T. Bittenbring, Homburg (Germany)
- 17:35 104 BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R-BM) INDUCTION FOLLOWED BY RITUXIMAB CONSOLIDATION IN ELDERLY DE NOVO ADVANCED STAGE FOLLICULAR LYMPHOMA (FL) PATIENTS: A STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)  
C. Boccomini, Turin (Italy)
- 17:45 105 MAJOR RESPONSES IN OVER 90% OF OLDER PATIENTS TREATED WITH F(C)R BASED CHEMOTHERAPY - THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) CLL5/OFOCIR STUDY  
S.P. Mulligan, Sydney (Australia)
- 17:55 106 SAFETY AND EFFICACY OF ABBREVIATED INDUCTION WITH ORAL FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C) COMBINED WITH DOSE-DENSE IV RITUXIMAB (R) IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AGED  $\geq$  65 YEARS: RESULTS OF A MULTICENTER TRIAL (LLC 2007 SA) ON BEHALF OF THE FRENCH GOELAMS/FCGCLL/WM INTERGROUP  
E. Van Den Neste, Brussels (Belgium)
- 18:05 107 FIRST LINE THERAPY OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – LONG TERM FOLLOW-UP (FU) RESULTS OF A RANDOMIZED PHASE III STUDY OF THE GERMAN CLL STUDY GROUP (CLL5 STUDY OF THE GCLLSG)  
B. Eichhorst, Cologne (Germany)
- 17:15 – 18.15 **MANTLE CELL LYMPHOMA** (USI Aula Magna, University Campus Lugano)  
Chair: J.P. Leonard, New York, NY (USA)
- 17:15 108 DEEP B AND T CELL REPERTOIRE SEQUENCING TO EVALUATE MINIMAL RESIDUAL DISEASE AND T CELL RESPONSES IN A THERAPEUTIC VACCINE TRIAL FOR MANTLE CELL LYMPHOMA  
R. Levy, Stanford, CA (USA)
- 17:25 109 REPROGRAMMING MCL FOR CYTOTOXIC KILLING BY TARGETING CDK4/CDK6  
S. Chen-Kiang, New York, NY (USA)
- 17:35 110 *A HIGH PIK3CA/PIK3CD* MRNA RATIO IN MANTLE CELL LYMPHOMA CAN PREDICT RESISTANCE TO PI3K $\delta$  INHIBITION AND IS MORE COMMON WITH MULTIPLE RELAPSE  
S. Iyengar, London (UK)
- 17:45 111 RADIOIMMUNOTHERAPY AS CONSOLIDATION IN MCL (MANTLE CELL LYMPHOMA) – 8 YEARS FOLLOW-UP OF A PROSPECTIVE PHASE 2 POLISH LYMPHOMA RESEARCH GROUP STUDY  
W. Jurczak, Krakow (Poland)



17:55 112 OUTCOME AFTER RIC ALLO-STEM CELL TRANSPLANTATION FOR PATIENTS WITH MANTLE CELL LYMPHOMA WHO RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION, A RETROSPECTIVE STUDY OF THE SFGM-TC GROUP  
S. Le Gouill, Nantes (France)

18:05 113 TARGETING THE IRF4/MYC AXIS IN BORTEZOMIB-RESISTANT MANTLE CELL LYMPHOMA WITH LENALIDOMIDE AND BET BROMODOMAIN INHIBITION  
G. Roue, Barcelona (Spain)

19:00 – 21:00  
(parallel satellite symposia)

prIME ONCOLOGY

**OPTIMIZING OUTCOMES FOR INDOLENT NON-HODGKIN LYMPHOMA AND MANTLE CELL LYMPHOMA**

(room A)

Chair: J.O. Armitage, Omaha, NE (USA)

MUNDIPHARMA INTERNATIONAL LTD.

**CAN WE ERADICATE THE CNS DISEASE IN LYMPHOMA?**

(room B)

Chairs: C. Gisselbrecht, Paris (France) and E. Thiel, Berlin (Germany)

## Friday, June 21, 2013

---

8:30 – 18:30 **POSTER SESSION** (Marquee Parco Ciani)

8:00 – 8:45 **MEET THE PROFESSOR SESSIONS** 

(5 parallel sessions, repetition of some of Wednesday session)

- XII. HODGKIN'S LYMPHOMA IN THE ELDERLY (room A)  
A.M. Evens, Worcester, MA (USA)
- IX. CLL: NEW GENETIC MARKERS AS PROGNOSTIC FACTORS (room B)  
D. Rossi, Novara (Italy)
- X. EXTRANODAL LYMPHOMAS IN RARE LOCALISATIONS (BONE, BREAST AND OTHERS) (Cinema Corso)  
J.F. Seymour, Melbourne (Australia)
- XIV. THE RATIONALE FOR COMBINING TARGETED AND BIOLOGICAL ANTI-LYMPHOMA DRUGS (USI Auditorium, University Campus Lugano)  
A. Younes, New York, NY (USA)
- XVI. CNS PROPHYLAXIS IN AGGRESSIVE LYMPHOMAS: FOR WHOM AND HOW (USI Aula Magna, University Campus Lugano)  
U. Vitolo, Turin (Italy)

9:00 – 10:30 **SESSION 8 – TARGETING THE LYMPHOMA EPIGENOME** (room A and Marquee)  
Chair: L. Pasqualucci, New York, NY (USA) and A. Younes, New York, NY (USA)

9:00 Introduction: L. Pasqualucci, New York, NY (USA)

- 9:15 114 THE BRD-INHIBITOR OTX015 IS ACTIVE IN PRE-CLINICAL B-CELL LYMPHOMA MODELS AND AFFECTS RELEVANT PATHOGENETIC PATHWAYS  
F. Bertoni, Bellinzona (Switzerland)
- 9:30 115 PRECLINICAL CHARACTERIZATION OF E7438, A POTENT, SELECTIVE INHIBITOR OF PROTEIN METHYLTRANSFERASE EZH2 WITH ROBUST ANTITUMOR ACTIVITY AGAINST EZH2 MUTATED NON-HODGKIN LYMPHOMA XENOGRAFTS IN MICE  
K. Kuntz, Cambridge, MA (USA)
- 9:45 116 SIRTUIN AND PAN-CLASS I/II DEACETYLASE (DACI) INHIBITION IS SYNERGISTIC IN PRECLINICAL MODELS AND CLINICAL STUDIES OF LYMPHOMAS  
O.A. O'Connor, New York, NY (USA)
- 10:00 117 THE PAN-HISTONE DEACETYLASE INHIBITOR (HDACI) ABEXINOSTAT (PCI-24781): SIGNIFICANT CLINICAL ACTIVITY IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) IN A MULTICENTER PHASE II STUDY  
A.M. Evens, Worcester, MA (USA)
- 10:15 118 A PHASE IB/II TRIAL OF ROMIDEPSIN IN ASSOCIATION WITH CHOP IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL): THE RO-CHOP STUDY  
J. Dupuis, Créteil (France)

9:00 – 10:30  
(4 parallel sessions)

**“CASE DISCUSSION” SESSIONS**

**AGGRESSIVE LYMPHOMAS** (room B)

Chair: J.W. Friedberg, Rochester, NY (USA)

Discussants: G.S. Nowakowski, Rochester, MN (USA) and G. Salles, Pierre Bénite (France)

**CLL** (Cinema Corso)

Chair: G. Gaidano, Novara (Italy)

Discussants: T.D. Shanafelt, Rochester, MN (USA) and L. Ysebaert, Toulouse (France)

**EXTRANODAL LYMPHOMAS** (USI Auditorium, University Campus Lugano)

Chair: M. Gospodarowicz, Toronto, Ontario (Canada)

Discussants: P.B. Johnston, Rochester, MN (USA) and T. Lamy de La Chapelle, Rennes (France)

**MCL** (USI Aula Magna, University Campus Lugano)

Chair: M. Dreyling, Munich (Germany)

Discussants: T.M. Habermann, Rochester, MN (USA) and S. Le Gouill, Nantes (France)

10:30 – 10:50

**COFFEE BREAK** (Marquee Parco Ciani)

11:00 – 18:00

**FIRST NURSING SESSION\*** (Auditorium, University Campus Lugano)

Chair: M. Bianchi, Bellinzona (Switzerland)

\* organized by Oncology Institute of Southern Switzerland (IOSI) and European Institute of Oncology (IEO)

(Official language: Italian - no translation provided)

10:50 – 12:05

**SESSION 9 – DLBCL TREATMENT STRATEGIES** (room A, B and Marquee)

Chairs: L. Specht, Copenhagen (Denmark) and K. Tobinai, Tokyo (Japan)

10:50

119

RITUXIMAB MAINTENANCE TREATMENT VERSUS OBSERVATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: RESULTS OF THE AGMT NHL13 TRIAL  
U. Jaeger, Wien (Austria)

11:05

120

CHEMOIMMUNOTHERAPY WITH R-CHOP OR HIGH DOSE SEQUENTIAL THERAPY (R-HDS) WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIGH RISK DLBCL PATIENTS: PRELIMINARY RESULTS OF THE RANDOMIZED R-HDS0305 TRIAL BY GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI (GITIL)  
S. Cortelazzo, Bolzano (Italy)

11:20

121

ROLE OF RADIATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: A COMPREHENSIVE ANALYSIS FROM THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) LYMPHOMA OUTCOMES PROJECT  
B. Dabaja, Houston, TX (USA)

11:35

122

THE ROLE OF RADIOTHERAPY TO BULKY DISEASE IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA. RESULTS FROM 2 PROSPECTIVE TRIALS OF THE DSHNHL  
C. Zwick, Homburg (Germany)

- 11:50 123 LONG-TERM EXPERIENCE WITH PET-GUIDED CONSOLIDATIVE RADIATION THERAPY (XRT) IN PATIENTS WITH ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP  
L.H. Sehn, Vancouver, BC (Canada)
- 12:05 – 13:00 **LUNCH TIME AND PRESENTATION OF BEST “CLINICAL” POSTERS**  
(Marquee Parco Ciani)  
by M. Dreyling, Munich (Germany)  
POSTERS # 188, 194, 196, 214, 217 and 226
- 13:00 – 14:00 **JOHN ULTMANN LECTURE \*** (room A, B and Marquee Parco Ciani)   
\* ASCO-ICML joint symposium  
Chair: G.B. Canellos, Boston, MA (USA)  
003 HODGKIN LYMPHOMA – THE GREAT TEACHER  
J.M. Connors, Vancouver, BC (Canada)
- 14:00 – 15:15 **SESSION 10 – FRONT-LINE TREATMENT OF HODGKIN'S LYMPHOMA**  
(room A, B and Marquee)  
Chairs: A. Engert, Cologne (Germany) and R. Pettengell, London (UK)
- 14:00 124 A PHASE II TRIAL OF RESPONSE-ADAPTED THERAPY OF STAGE III-IV HODGKIN LYMPHOMA USING EARLY INTERIM FDG-PET IMAGING: U.S. INTERGROUP S0816  
O.W. Press, Seattle WA (USA)
- 14:15 125 PET-CT ADAPTED THERAPY AFTER 3 CYCLES OF ABVD TO ALL STAGES OF HODGKIN LYMPHOMA: A REPORT FROM THE GATLA GROUP  
A. Pavlovsky, Buenos Aires (Argentina)
- 14:30 126 RESPONSES AND CHEMOTHERAPY DOSE ADJUSTMENT DETERMINED BY PET-CT IMAGING: FIRST RESULTS FROM THE INTERNATIONAL RESPONSE ADAPTED THERAPY IN ADVANCED HODGKIN LYMPHOMA (RATHL) STUDY  
P.W.M. Johnson, Southampton (UK)
- 14:45 127 ABVD (8 CYCLES) VS. BEACOPP (4 ESCALATED CYCLES => 4 BASELINE) IN STAGE III - IV LOW RISK HODGKIN LYMPHOMA (IPS 0-2): FINAL RESULTS OF LYSA H34 TRIAL  
N. Mounier, Nice (France)
- 15:00 128 **REPORT OF 11-ICML CLOSED WORKSHOP** ON “LYMPHOMA PRETREATMENT ASSESSMENT AND RESPONSE CRITERIA IN THE NEW MILLENNIUM: BEYOND ANN ARBOR”  
B.D. Cheson, Washington D.C. (USA)
- 15:15 **BREAK**
- 15:30 – 16:15 **CONTROVERSY II** (room A, B and Marquee)  
DOES RADIOTHERAPY REMAIN THE STANDARD COMPONENT OF TREATMENT IN EARLY STAGE HODGKIN LYMPHOMA?  
Chair: B.D. Cheson, Washington D.C. (USA)  
129 YES – T. Illidge, Manchester (UK) vs  
130 NO – M. Gospodarowicz, Toronto, Ontario (Canada)

- 16:15 – 17:35      **PRESENTATION OF ONGOING TRIALS** (room A, B, C and Marquee)  
Chairs: R.I. Fisher, Philadelphia, PA (USA) and M. Federico, Modena (Italy)
- 16:15            131      PHASE 3 TRIAL COMPARING GA101 (OBINUTUZUMAB) + CHOP (G-CHOP) VS RITUXIMAB + CHOP (R-CHOP) IN PREVIOUSLY UNTREATED DLBCL  
M. Mobasher, South San Francisco, CA (USA)
- 16:25            132      GENE EXPRESSION PROFILING (GEP) TO IDENTIFY SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL) FOR RANDOMISATION TO R-CHOP +/- BORTEZOMIB. A TRIAL IN PROGRESS IN THE UK NCRI AND SAKK LYMPHOMA GROUPS: REMODL-B, ISRCTN51837425  
A. Davies, Southampton (UK)
- 16:35            133      A RANDOMISED, MULTICENTRE, TWO-ARM PHASE III COMPARATIVE STUDY ASSESSING THE ROLE OF MEDIASTINAL RADIOTHERAPY AFTER RITUXIMAB-CONTAINING CHEMOTHERAPY REGIMENS TO PATIENTS WITH NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL). THE IELSG37 STUDY  
M. Martelli, Rome (Italy)
- 16:45            134      CLLM1: A RECRUITING PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE AS MAINTENANCE THERAPY FOR HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA FOLLOWING FIRST-LINE THERAPY  
A.M. Fink, Cologne (Germany)
- 16:55            135      A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (GS-1101) IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR PREVIOUSLY TREATED INDOLENT NON-HODGKIN LYMPHOMAS (INHL)  
M.S. Czuczman, Buffalo, NY (USA)
- 17:05            136      THE "RELEVANCE" TRIAL: A LYSA SPONSORED PHASE 3 RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS ANY CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA  
F. Morschhauser, Lille (France)
- 17:15            137      A PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB (BR) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL)  
M. Dreyling, Munich (Germany)
- 17:25            138      ECHELON-2: PHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+ MATURE T-CELL LYMPHOMAS (MTCL)  
O.A. O'Connor, New York, NY (USA)
- 17:35 – 18:35      **FAREWELL APERO** (Marque Parco Ciani)

18:45 – 19:45

IOSI – ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND (*supported by an unrestricted educational grant from MUNDIPHARMA INTERNATIONAL LTD.*)

**PROS AND CONS OF FRONT LINE R-CHOP PLUS MAINTENANCE IN FL**

(room B)

Chair: M. Ghielmini, Bellinzona (Switzerland)


## Saturday, June 22, 2013


---

- 8:00–10:30 **SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING\*** (USI room 159 - University Campus Lugano)  
Chairs: L. Specht, Copenhagen (Denmark) and J. Yahalom, New York, NY (USA)  
\*Organized by ILROG – International Lymphoma Radiation Oncology Group and endorsed by ESTRO – European Society for Radiotherapy and Oncology (for lymphoma radiation oncologists: maximum number 30. Registration closed)
- 8:30 – 9:30  
(2 parallel sessions) **“FOCUS ON...” SESSIONS**
- RELAPSING/REFRACTORY HODGKIN'S LYMPHOMA** (room A)  
Chair: T.A. Lister, London (UK)
- 8:30 139 PILOT PHASE 2 STUDY OF IDELALISIB, A SELECTIVE INHIBITOR OF PI3K $\delta$ , IN PATIENTS WITH HEAVILY PRETREATED HODGKIN LYMPHOMA (HL)  
A. Younes, New York, NY (USA)
- 8:40 140 TWO-YEAR FOLLOWUP OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN TREATED WITH BRENTUXIMAB VEDOTIN PRIOR TO REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION  
R. Chen, Duarte, CA (USA)
- 8:50 141 PET-ADAPTED SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED-ICE INDUCES FDG-PET NORMALIZATION IN 92% OF PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA  
A.J. Moskowitz, New York, NY (USA)
- 9:00 142 PROGNOSTIC FACTORS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) HODGKIN'S LYMPHOMA (HL) TREATED WITH IGEV AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT ): A NATIONWIDE RETROSPECTIVE SURVEY FROM FONDAZIONE ITALIANA LINFOMI (FIL)  
M. Balzarotti, Rozzano (Italy)
- 9:10 143 LONG-TERM OUTCOME OF ADULTS WITH FIRST RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED IN THE PROSPECTIVE LYSA/SFGM-TC H96 TRIAL  
D. Sibon, Paris (France)
- 9:25 144 SERUM TARC LEVEL MONITORING MAY PREDICT DISEASE RELAPSE DETECTED BY PET SCAN AFTER REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMA PATIENTS  
L. Farina, Milan (Italy)
- 8:30 – 9:30 **PHASE I-II TRIALS** (room B)  
Chair: A.H. Goy, Hackensack, NJ (USA)
- 8:30 145 PRELIMINARY SAFETY AND EFFICACY OF IPI-145, A POTENT INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE- $\delta$ , $\gamma$ , IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL  
I.W. Flinn, Nashville, TN (USA)

- 8:40 146 UPDATED RESULTS OF A PHASE I FIRST-IN-HUMAN STUDY OF THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)  
M. Davids, Boston, MA (USA)
- 8:50 147 CELL CYCLE INHIBITION WITH PD0332991 SENSITIZES MCL TO KILLING BY BORTEZOMIB: A PHASE I TRIAL  
P. Martin, New York, NY (USA)
- 9:00 148 PHASE 1 STUDY OF R-CVP PLUS INOTUZUMAB OZOGAMICIN (INO) IN CD22+ B-CELL NON-HODGKIN LYMPHOMA (B-NHL)  
M. Ogura, Nagoya (Japan)
- 9:10 149 TEMSIROLIMUS ADDED TO BENDAMUSTIN AND RITUXIMAB (BERT): PHASE I RESULTS OF A PHASE I/II-TRIAL IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL) AND MANTLE CELL LYMPHOMA (MCL)  
G. Hess, Mainz (Germany)
- 9:20 150 PROSPECTIVE PHASE II CLINICAL TRIAL OF CARFILZOMIB, RITUXIMAB AND DEXAMETHASONE (CARD) IN WALDENSTROM'S MACROGLOBULINEMIA (WM)  
S.P. Treon, Boston, MA (USA)
- 9:45-11:00  
(2 parallel sessions) **SESSION 11 – T-CELL NEOPLASIA** (room A)  
Chairs: C. Gisselbrecht, Paris (France) and J.M. Vose, Omaha, NE (USA)
- 9:45 151 CD30 IN PTCLS: CORRELATION BETWEEN RNA AND PROTEIN LEVELS IN A LARGE EUROPEAN SERIES FROM THE LYSA  
C. Bossard, Nantes (France)
- 10:00 152 SAFETY AND EFFICACY OF BRENTUXIMAB VEDOTIN FOR TREATMENT OF RELAPSED OR REFRACTORY MATURE T-/NK-CELL LYMPHOMAS  
Y. Oki, Houston, TX (USA)
- 10:15 153 BELINOSTAT IN RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA (R/R PTCL) SUBTYPE ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL): RESULTS FROM THE PIVOTAL BELIEF TRIAL  
S. Horwitz, New York, NY (USA)
- 10:30 154 COMBINATION OF MOGAMULIZUMAB (KW-0761) WITH VCAP-AMP-VECP (MLSG15) IS WELL TOLERATED AND EFFECTIVE AS AN INITIAL THERAPY FOR AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA (ATL)  
S. Takemoto, Kumamoto (Japan)
- 10:45 155 INTENSIFIED CHEMO-IMMUNOTHERAPY FOR PATIENTS AFFECTED BY NODAL PERIPHERAL T-CELL LYMPHOMAS (PTCLS) AT DIAGNOSIS: FINAL RESULTS OF A PHASE II MULTICENTER PROSPECTIVE TRIAL  
P. Corradini, Milan (Italy)
- 9:45-11:15 **SESSION 12 – LYMPHOMA MICROENVIRONMENT** (room B)  
Chairs: E. Campo, Barcelona (Spain) and J.P. Leonard, New York, NY (USA)
- 9:45 Introduction: E. Campo, Barcelona (Spain)



- 10:00 156 T-CELL AND MONOCYTE PROFILING SHOWS MARKED DIFFERENCES IN FRESH TISSUE GENE EXPRESSION BETWEEN POSITIVELY SELECTED TUMOUR INFILTRATING AND PERIPHERAL BLOOD CELLS IN FOLLICULAR NON-HODGKIN'S LYMPHOMA (FL): POSSIBLE ROLE OF HEAT SHOCK PROTEIN 70 (HSP70) AND B-CELL RECEPTOR ACTIVATING GENES IN DISEASE PROGRESSION AND TRANSFORMATION  
S.M. Rassam, Kent (UK)
- 10:15 157 A DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED-MACROPHAGE TRANSCRIPTOME ANALYSIS REVEALS A UNIQUE M1-M2 POLARIZATION PROFILE THAT CHALLENGES CURRENT CONCEPTS ON THE LYMPHOMA MICROENVIRONMENT  
R. Coutinho, London (UK)
- 10:30 158 CSF-1R INHIBITION DEPLETES TUMOR-ASSOCIATED MACROPHAGES AND IS A RATIONAL NOVEL CLINICAL STRATEGY IN AGGRESSIVE B-LYMPHOMAS  
S. Hallam, London (UK)
- 10:45 159 PHASE II SAFETY AND EFFICACY STUDY OF PIDILIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA  
J.R. Westin, Houston, TX (USA)
- 11:00 160 CD163+ IDENTIFIES A HIGHLY IMMUNOSUPPRESSIVE SUBSET OF MONOCYTIC-MYELOID DERIVED SUPPRESSOR CELLS (MOMDSC) IN POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN ALLG LABORATORY SUB-STUDY OF NHL21  
C. Keane, Brisbane (Australia)
- 11:15 -11:45 **12-ICML HIGHLIGHTS** (room A, B)   
"TAKE HOME MESSAGES"  
J.O. Armitage, Omaha, NE (USA)
- 13:15 – 18:00 **WORKSHOP: "CANINE LYMPHOMAS: STATE OF THE ART AND COMPARATIVE ASPECTS WITH HUMAN DISEASE"**\*  
(open to all 12-ICML attendees - room B)  
Chairs: S. Comazzi, F. Guscelli and L. Marconato, Milan (Italy)  
\*organized by the European Canine Lymphoma Group

 This icon denotes presentations that will be available online, only for ICML attendees, between July 15 and September 15, 2013.